SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

Abstract

Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future.

Outcome of dogs treated with chemotherapy for mesothelioma: A retrospective clinical study on 40 cases and a literature review

“…Finally, as in humans, canine mesothelioma seems to mainly concern pleural cavity; though, pericardial cavity may be more frequently involved in dogs. 11,74 Medical imaging of the neoplastic cavity is required during the diagnosis of mesothelioma, especially to exclude other cause of effusion. Indeed, little is known about mesothelioma imaging; two studies on thoracic CT images of malignant and benign diseases showed parietal pleura thickening, nodular diaphragmatic thickening and thoracic wall invasion to be associated with thoracic malignancies.…”

“…Pleural cavity imaging was performed in 37 dogs (92.5%) with computed tomography (CT) scan (19), radiographs (27) or, ultrasonography (11).…”

Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma

“…In mesothelioma patients, most mesothelioma cells spread into the diaphragm, chest wall, and mediastinum; radiotherapy is therefore limited due to the high risk of injury to the lungs and surrounding organs [30]. Radiation pneumonitis is the most common toxicity in patients treated with radiation for cancers in the thorax [31].…”

Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with The Novel Antibody NZ-16 for Malignant Mesothelioma

“…In mesothelioma patients, most mesothelioma cells spread into the diaphragm, chest wall, and mediastinum; radiotherapy is therefore limited due to the high risk of injury to the lungs and surrounding organs [28]. Radiation pneumonitis is the most common toxicity in patients treated with radiation for cancers in the thorax [29].…”